The present invention relates to a transdermal therapeutic system (TTS) comprising an impermeable covering layer, a matrix containing an ergolin compound of formula (I) or the physiologically compatible salt or derivative thereof, wherein R1 represents an H atom or a halogen atom and R2 an alkyl group with 1 to 4 carbon atoms and ------ a single or double bond, and a removable protective layer, the ergolin compound or the physiologically compatible salt or derivative thereof being stabilized by an antioxidant and a basic polymer. The TTS is characterized in that the matrix contains at least one hydrocarbon having 8 to 18 carbon atoms in a linear or branched chain and carrying a functional group at the end of the alkyl chain, and/or aloe vera oil so that, in a first phase (0-5 hours after application), only 0 to 20 % of the therapeutically desired steady state plasma concentration of the ergolin compound is achieved and, in a second phase (5-20 hours after application), the therapeutically desired steady state plasma concentration of the ergolin compound is achieved.